Using Protein Biomarkers Enhances Clinical Trial Outcomes
It is crystal clear that clinical trials are the surest way to bring new drugs into the market. While most clinical trials are costly, nine out of ten drugs in clinical development are never approved. Most of these treatments fail in clinical trials due to a lack of the desired effect, and some of these failures are attributed to poor target selection during the drug discovery process. Matching the right treatment to the right patient based on molecular biomarkers can bring more promising results in clinical trials. Precision Medicine Requires Reliable Biomarkers Precision medicine aims to treat patients as individuals.…